Table 1.

Demographics and clinical characteristics of 29 patients with advanced TRK fusion-positive thyroid carcinoma treated with larotrectinib.

Characteristics	All	PTC/FTC	ATC
n	29	22	7
Age at study enrolment, median (range), years	60.0 (6.0–80.0)	58.0 (6.0–80.0)	64.0 (49.0–77.0)
Paediatric (<18 years)	2 (7)	2 (9)	0
Adult (≥18 years)	27 (93)	20 (91)	7 (100)
Sex, n (%)
Female	20 (69)	15 (68)	5 (71)
Male	9 (31)	7 (32)	2 (29)
ECOG performance status, n (%)
0	12 (41)	11 (50)	1 (14)
1	12 (41)	8 (36)	4 (57)
2	4 (14)	3 (14)	1 (14)
3	1 (3)	0	1 (14)
Cancer subtype, n (%)
Papillary*	20 (69)	20 (91)	0
Follicular	2 (7)	2 (9)	0
Anaplastic*	7 (24)	0	7 (100)
Brain metastases at baseline, n (%)
Yes	4 (14)	4 (18)	0
No	25 (86)	-	-
Prior therapies†, n (%)
Surgery	29 (100)	22 (100)	7 (100)
Radiotherapy	17 (59)	12 (55)	5 (71)
RAI	23 (79)	21 (95)	2 (29)
Systemic therapy†‡	16 (55)	13 (59)	3 (43)
Tyrosine kinase inhibitors	11 (38)	11 (50)	0
Immunotherapy	2 (7)	2 (9)	0
Chemotherapy	3 (10)	0	3 (43)
Number of prior systemic therapies, n (%)
0	13 (45)	9 (41)	4 (57)
1	7 (24)	4 (18)	3 (43)
2	7 (24)	7 (32)	0
≥3	2 (7)	2 (9)	0
NTRK gene, n (%)
NTRK1	13 (45)	10 (45)	3 (43)
NTRK3	16 (55)	12 (55)	4 (57)

*One patient classified as PTC and two patients classified as ATC had PDTC. ^†Patients may be counted in more than 1 category. ^‡Including cabozantinib, cisplatin, doxorubicin, ipilimumab, lenvatinib, paclitaxel, pazopanib, pembrolizumab, sorafenib, sunitinib and trametinib.

ATC, anaplastic thyroid carcinoma; ECOG, Eastern Cooperative Oncology Group; FTC, follicular thyroid carcinoma; NTRK, neurotrophic tyrosine receptor kinase; PDTC, poorly differentiated thyroid carcinoma; PTC, papillary thyroid carcinoma; RAI, radioactive iodine; TRK, tropomyosin receptor kinase.